<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333098</url>
  </required_header>
  <id_info>
    <org_study_id>201011836</org_study_id>
    <nct_id>NCT01333098</nct_id>
  </id_info>
  <brief_title>Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders</brief_title>
  <acronym>Mifepristone</acronym>
  <official_title>Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to develop and test a novel, mechanistic treatment for mitigating cognitive
      impairment in older adults with anxiety disorders. Anxiety disorders are common, severe, and
      disabling in older adults. One particularly impairing aspect of late-life anxiety disorders
      is cognitive impairment: impairments in memory and executive function cause disability,
      impede treatment response to psychotherapy, may lead to dementia, and are not corrected by
      standard anti-anxiety treatments.

      This pilot study will test the glucocorticoid antagonist, mifepristone, for cognitive
      impairment in late-life anxiety disorders. Mifepristone blocks the effects of elevated
      cortisol levels on glucocorticoid receptors in the brain; it has been studied preliminarily
      in various neuropsychiatric disorders, such as psychotic depression and bipolar disorder,
      with well-documented safety and tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, no treatment exists to address cognitive impairment in late-life anxiety
      disorders. In this study, fifteen patients aged 60+ with an anxiety disorder (current or in
      partial remission) and subjective and/or objective evidence of cognitive impairment will
      receive treatment with mifepristone. At the baseline visit participants will be randomized to
      receive either mifepristone 300mg or a placebo daily for 7 days. Participants will be
      reassessed after 7 days (week 1 visit) of receiving study medication (mifepristone or
      placebo). At that time all participants will be provided mifepristone 300mg daily for the
      remaining 3 weeks of study treatment. The primary outcome measure will be neurocognition, as
      assessed by a battery of neuropsychological measures focusing on immediate and delayed memory
      and executive function (administered at baseline, week 1, week 4, and week 12). Saliva
      samples for cortisol measurement will be collected immediately following the baseline visit
      and week 4 visit. Secondary outcomes will be self-reported anxiety and depressive symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>In the first week, participants were randomly assigned to mifepristone 300mg daily or placebo. In the subsequent 3 weeks, all participants received mifepristone 300mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects</measure>
    <time_frame>Baseline, Week 2, Week 4</time_frame>
    <description>number of participants with dose-limiting side effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Self-reported Side Effects</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Changes Over Time, as Measured by Between Group and Within-subjects Comparison of Neuropsychological Measures.</measure>
    <time_frame>Baseline, Week 4, Week 12</time_frame>
    <description>Memory composite z-score: The two memory measures were a 16-word list recall similar to the Rey auditory verbal learning test, which has been used by the Washington University Alzheimer's Disease Research Center; and two paragraphs from a set of paragraph recall tests validated as sensitive to effects of stress-level glucocorticoids. For each memory variable, a z score was computed for each participant, where z score = (participant score mean)/standard deviation. Then a single composite memory variable was created by summing up these z scores. Summed Z-scores range from -6 to 6, with scores above 0 being higher than the mean.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety Symptoms</measure>
    <time_frame>baseline, week 4, week 12</time_frame>
    <description>Self-report assessment of worry using Penn State Worry Questionnaire- Abbreviated, an 8-item measure (range 8-40 with high scores indicating higher levels of anxiety and worry symptoms.The average score for older adults with generalized anxiety disorder is 22, while the mean score for healthy older adults is 15.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 week mifepristone or placebo (followed by 3 weeks open label mifepristone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>300mg per day, by mouth, for 21-28 days</description>
    <arm_group_label>mifepristone</arm_group_label>
    <other_name>Mifeprex</other_name>
    <other_name>RU-486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 65 and older

          -  Non-demented by clinical evaluation

          -  Current or partially remitted generalized anxiety disorder or panic disorder

          -  Currently taking antidepressant treatment with stable dose for at least 8 weeks

          -  Memory impairment

        Exclusion Criteria:

          -  Mild to severe dementia

          -  Diabetes

          -  Current alcohol or substance abuse

          -  Current or lifetime psychotic symptoms, bipolar disorder, or eating disorder

          -  Untreated endocrinologic disease

          -  Lifetime Cushing's or Addison's disease

          -  Current cancer

          -  History of metastatic cancer

          -  Current use of systemic corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric J Lenze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/enhanced/doi/10.1002/gps.4085</url>
    <description>2012</description>
  </link>
  <results_reference>
    <citation>Lenze EJ, Hershey T, Newcomer JW, Karp JF, Blumberger D, Anger J, Dor√© P, Dixon D. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone. Int J Geriatr Psychiatry. 2014 Sep;29(9):962-9. doi: 10.1002/gps.4085. Epub 2014 Mar 14.</citation>
    <PMID>24633761</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <results_first_submitted>April 5, 2018</results_first_submitted>
  <results_first_submitted_qc>March 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2019</results_first_posted>
  <last_update_submitted>March 15, 2019</last_update_submitted>
  <last_update_submitted_qc>March 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anxiety</keyword>
  <keyword>older adult</keyword>
  <keyword>memory</keyword>
  <keyword>cognitive</keyword>
  <keyword>Saint Louis</keyword>
  <keyword>treatment</keyword>
  <keyword>cognitive impariment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mifepristone</title>
          <description>1 week mifepristone or placebo, followed by 3 weeks open label mifepristone
Mifepristone: 300mg per day, by mouth, for 21-28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mifepristone</title>
          <description>1 week mifepristone or placebo followed by 3 weeks open label mifepristone
Mifepristone: 300mg per day, by mouth, for 21-28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.1" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects</title>
        <description>number of participants with dose-limiting side effects</description>
        <time_frame>Baseline, Week 2, Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone</title>
            <description>1 week mifepristone or placebo, followed by 3 weeks open label mifepristone
Mifepristone: 300mg per day, by mouth, for 21-28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects</title>
          <description>number of participants with dose-limiting side effects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Self-reported Side Effects</title>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone</title>
            <description>1 week mifepristone or placebo, followed by 3 weeks open label mifepristone
Mifepristone: 300mg per day, by mouth, for 21-28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Self-reported Side Effects</title>
          <units>participants with reported side effects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Changes Over Time, as Measured by Between Group and Within-subjects Comparison of Neuropsychological Measures.</title>
        <description>Memory composite z-score: The two memory measures were a 16-word list recall similar to the Rey auditory verbal learning test, which has been used by the Washington University Alzheimer's Disease Research Center; and two paragraphs from a set of paragraph recall tests validated as sensitive to effects of stress-level glucocorticoids. For each memory variable, a z score was computed for each participant, where z score = (participant score mean)/standard deviation. Then a single composite memory variable was created by summing up these z scores. Summed Z-scores range from -6 to 6, with scores above 0 being higher than the mean.</description>
        <time_frame>Baseline, Week 4, Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Baseline Cortisol</title>
            <description>baseline peak cortisol &gt;6 ng/ml</description>
          </group>
          <group group_id="O2">
            <title>Without High Baseline Corisol</title>
            <description>baseline peak cortisol &lt;6 ng/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Changes Over Time, as Measured by Between Group and Within-subjects Comparison of Neuropsychological Measures.</title>
          <description>Memory composite z-score: The two memory measures were a 16-word list recall similar to the Rey auditory verbal learning test, which has been used by the Washington University Alzheimer's Disease Research Center; and two paragraphs from a set of paragraph recall tests validated as sensitive to effects of stress-level glucocorticoids. For each memory variable, a z score was computed for each participant, where z score = (participant score mean)/standard deviation. Then a single composite memory variable was created by summing up these z scores. Summed Z-scores range from -6 to 6, with scores above 0 being higher than the mean.</description>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.58"/>
                    <measurement group_id="O2" value="-0.59" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="1.97"/>
                    <measurement group_id="O2" value="-0.45" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="2.20"/>
                    <measurement group_id="O2" value="-0.26" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety Symptoms</title>
        <description>Self-report assessment of worry using Penn State Worry Questionnaire- Abbreviated, an 8-item measure (range 8-40 with high scores indicating higher levels of anxiety and worry symptoms.The average score for older adults with generalized anxiety disorder is 22, while the mean score for healthy older adults is 15.</description>
        <time_frame>baseline, week 4, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Baseline Cortisol</title>
            <description>baseline peak cortisol &gt;6 ng/ml</description>
          </group>
          <group group_id="O2">
            <title>Without High Baseline Corisol</title>
            <description>baseline peak cortisol &lt;6 ng/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiety Symptoms</title>
          <description>Self-report assessment of worry using Penn State Worry Questionnaire- Abbreviated, an 8-item measure (range 8-40 with high scores indicating higher levels of anxiety and worry symptoms.The average score for older adults with generalized anxiety disorder is 22, while the mean score for healthy older adults is 15.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.80" spread="4.27"/>
                    <measurement group_id="O2" value="27.88" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.40" spread="6.09"/>
                    <measurement group_id="O2" value="27.00" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="6.02"/>
                    <measurement group_id="O2" value="25.29" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected during the course of each participant's 12 week participation in the study which took place during a 4 month period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mifepristone</title>
          <description>1 week mifepristone or placebo (followed by 3 weeks open label mifepristone)
Mifepristone: 300mg per day, by mouth, for 21-28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of pre-existing orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Reduced T4</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric Lenze, MD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-5154</phone>
      <email>lenzee@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

